References

  1. Amgen Canada Inc. Repatha® (evolocumab injection) Product Monograph. December 9, 2021.
  2. IQVIA. National TRx volume claims database. 2021.
  3. Pearson GJ, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Can J Cardiol. 2021;37(8):1129-1150.
  4. Sabatine MS, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713-1722.
  5. Robinson JG, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. Jama. 2014;311(18):1870-1882.
  6. Raal FJ, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331-340.
  7. Sabatine MS, et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J. 2016;173:94-101.
  8. Genest J, et al. Canadian Cardiovascular Society position statement on familial hypercholesterolemia. Can J Cardiol. 2014;30(12):1471-1481.
  9. Brunham LR, et al. Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. Can J Cardiol. 2018;34(12):1553-1563.
  10. Health Canada. Notice of Compliance Search. 2021. Available at: https://health-products.canada.ca/noc-ac/index-eng.jsp. Retrieved December 16, 2021.
  11. Amgen Canada Inc. Data on file (private insurance coverage). 2021.
  12. BC PharmaCare. Limited Coverage Drugs – evolocumab. 2021. Available at: https://www2.gov.bc.ca/gov/content/health/practitioner-pharmacare/prescribers/limited-coverage-drug-program/limited-coverage-drugs-evolocumab . Retrieved September 15, 2021.
  13. Alberta Blue Cross. Interactive Drug Benefit List. 2021. Available at: https://idbl.ab.bluecross.ca/idbl/. Retrieved September, 2021.
  14. Saskatchewan Go. Saskatchewan drug plan. 2021. Available at: http://formulary.drugplan.ehealthsask.ca/SearchFormulary. Retrieved September 15, 2021.
  15. Manitoba Pharmacare. Manitoba Drug Benefits and Interchangeability Formulary. 2021. Available at: https://www.gov.mb.ca/health/mdbif/. Retrieved September 15, 2021.
  16. Government of Ontario. Ontario Drug Benefit Formulary/Comparative Drug Index. 2021. Available at: https://www.formulary.health.gov.on.ca/formulary/. Retrieved September 15, 2021.
  17. RAMQ (official mark of the Régie de l'assurance maladie du Québec). List of Medications. 2021. Available at: https://www.ramq.gouv.qc.ca/en/about-us/list-medications. Retrieved September 15, 2021.
  18. Government of New Brunswick. NB Drug Plans Formulary Update. 2021. Available at: https://www2.gnb.ca/content/dam/gnb/Departments/h-s/pdf/en/NBDrugPlan/NewBrunswickDrugPlansFormulary.pdf . Retrieved September 15, 2021.
  19. Nova Scotia Pharmacare. Exception Status Drugs. 2021. Available at: https://novascotia.ca/dhw/pharmacare/exception-status-drugs.asp. Retrieved September 15, 2021.

You are now leaving the Repatha.ca website

The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk.

Proceed